Arf6 as a therapeutic target: Structure, mechanism, and inhibitors
Acta Pharmaceutica Sinica B, ISSN: 2211-3835, Vol: 13, Issue: 10, Page: 4089-4104
2023
- 5Citations
- 21Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- Captures21
- Readers21
- 21
- Mentions1
- News Mentions1
- News1
Most Recent News
Wuya College of Innovation Researchers Have Published New Study Findings on Cancer (Arf6 as a therapeutic target: Structure, mechanism, and inhibitors)
2023 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Data detailed on cancer have been presented. According to
Review Description
ADP-ribosylation factor 6 (Arf6), a small G-protein of the Ras superfamily, plays pivotal roles in multiple cellular events, including exocytosis, endocytosis, actin remodeling, plasma membrane reorganization and vesicular transport. Arf6 regulates the progression of cancer through the activation of cell motility and invasion. Aberrant Arf6 activation is a potential therapeutic target. This review aims to understand the comprehensive function of Arf6 for future cancer therapy. The Arf6 GEFs, protein structure, and roles in cancer have been summarized. Comprehending the mechanism underlying Arf6-mediated cancer cell growth and survival is essential. The structural features of Arf6 and its efforts are discussed and may be contributed to the discovery of future novel protein-protein interaction inhibitors. In addition, Arf6 inhibitors and mechanism of action are listed in the table. This review further emphasizes the crucial roles in drug resistance and attempts to offer an outlook of Arf6 in cancer therapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2211383523002113; http://dx.doi.org/10.1016/j.apsb.2023.06.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85163460225&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37799386; https://linkinghub.elsevier.com/retrieve/pii/S2211383523002113; https://dx.doi.org/10.1016/j.apsb.2023.06.008; http://sciencechina.cn/gw.jsp?action=cited_outline.jsp&type=1&id=7700217&internal_id=7700217&from=elsevier
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know